CompletedPhase 1NCT02390531
Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Studying Retinopathy of prematurity
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jaeb Center for Health Research
- Principal Investigator
- David K Wallace, MD, MPHIndiana University
- Intervention
- Bevacizumab(drug)
- Enrollment
- 120 target
- Eligibility
- All sexes
- Timeline
- 2015 – 2021
Study locations (11)
- The Emory Eye Center, Atlanta, Georgia, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Wilmer Institute, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Duke University Eye Center, Durham, North Carolina, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- Pediatric Ophthalmology Associates, Inc., Columbus, Ohio, United States
- Dean A. McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma, United States
- Texas Children's Hospital - Dept. Of Ophthalmology, Houston, Texas, United States
- University of Utah Moran Eye Center, Salt Lake City, Utah, United States
- Virginia Pediatric Eye Center, Norfolk, Virginia, United States
Collaborators
Pediatric Eye Disease Investigator Group · National Eye Institute (NEI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02390531 on ClinicalTrials.govOther trials for Retinopathy of prematurity
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07093255Safety, PK and PD of FLQ-101 in Premature NeonatesFELIQS INC.
- RECRUITINGNCT06612541Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of PrematurityVanderbilt University Medical Center
- ENROLLING BY INVITATIONNANCT07334652Pain and Comfort in the Examination of Retinopathy of PrematurityAtaturk University
- RECRUITINGNANCT06717412Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity TherapyWang Yusheng
- RECRUITINGNCT05558059Imaging Retinal Vasculature in Infant EyesDuke University
- ACTIVE NOT RECRUITINGNANCT06109285Validation of i-ROP DL to Detect More Than Mild ROPSiloam Vision
- RECRUITINGNCT06315556An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)Bayer
- RECRUITINGNANCT06694103The Effect of Two Non-Pharmacological Methods on Pain During Retinopathy ExaminationSinem Basdemir